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Background: Psoriasis is an inflammatory disease associated with increased risk of coronary artery disease.
However, the potential impact of psoriasis on the prognosis following percutaneous coronary revascularization (PCI)
is unknown.
Methods: The study comprised the entire Danish population undergoing first-time PCI in the period 2002–09. Cox
regression models, controlling for age, gender, socioeconomic status, pharmacological treatment, and comorbidity
were used to assess the risk of 1) all-cause mortality and 2) a composite endpoint of death, myocardial infarction,
and stroke.
Results: A total of 53,141 patients with first-time PCI in the study period were identified. Of these, 1074 had mild
psoriasis and 315 had severe psoriasis. Patients with severe psoriasis, but not those with mild disease had increased
risk of both endpoints compared to patients without psoriasis. The incidence rates for all-cause mortality were 30.5
(CI 29.7-31.3), 29.9 (CI 24.7-36.1), and 47.2 (CI 35.0-63.6) per 1000 patient years for patients without psoriasis, with
mild psoriasis, and with severe psoriasis, respectively. Hazard ratios were 1.10 (CI 0.91-1.33) and 1.67 (CI 1.24-2.26) for
mild and severe psoriasis, respectively. Patients with severe psoriasis were less likely to receive secondary prevention
pharmacotherapy with betablockers, statins and platelet inhibitors.
Conclusion: This first study of the prognosis following PCI in patients with psoriasis demonstrated an increased risk
of all-cause mortality and of a composite of death, myocardial infarction and stroke, respectively, in patients with
severe psoriasis compared to patients without psoriasis. Further studies of this novel association are needed.
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Psoriasis is a chronic inflammatory disease affecting the
skin of 1-3% of the population [1]. Other manifestations
of psoriasis include scalp psoriasis, nail disease, and
sero-negative arthritis known as psoriatic arthritis [1].
Atherosclerosis is also regarded as an inflammatory dis-
ease and the underlying mechanisms are very similar to
those seen in psoriasis [2,3]. Furthermore, psoriasis is* Correspondence: olahha01@geh.regionh.dk
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reproduction in any medium, provided the orassociated with conventional cardiovascular risk factors,
including diabetes mellitus, hypertension, and dyslipide-
mia [4,5]. Like other inflammatory disorders including
rheumatoid arthritis and systemic lupus erythromatosus,
psoriasis confers independent risk of atherothrombotic
disease, invasive coronary revascularization, and cardio-
vascular mortality [6-11]. In the Danish population,
patients with psoriasis have been demonstrated to have
an increased (1.4 to 2.3 fold) risk of coronary revascular-
ization, including percutaneus coronary intervention
(PCI) [9]. Recent results have indicated that patients with
psoriasis face a poorer prognosis following myocardial in-
farction compared to patients without psoriasis [12].
Although PCI is widely used in the treatment of acutel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Ahlehoff et al. BMC Cardiovascular Disorders 2012, 12:79 Page 2 of 8
http://www.biomedcentral.com/1471-2261/12/79and chronic coronary artery disease there are no data
available on the potential impact of psoriasis on post-PCI
prognosis.
We therefore used the Danish nationwide registries to
examine the psoriasis-related risks of death, myocardial
infarction, stroke, and repeat revascularization in patients
with and without psoriasis after first-time PCI in the
time-period 2002–2009.
Results
Baseline characteristics of the study population are
presented in Table 1. A total of 53,141 patients, in-
cluding 1074 with mild psoriasis and 315 with severe
psoriasis, with first-time PCI in the study period were
identified. Patients with severe psoriasis were slightly
younger and more often women compared to patients
without psoriasis. In approximately 55–60% the index
PCIs were performed in patients with a previous
myocardial infarction, including 26–29% primary PCITable 1 Baseline characteristics of the study population
No psoriasis
n=51,752
Male (%) 36,989 (71.5)
Female (%) 14,763 (28.5)
Age, years (SD) 65.1 (11.6)
Treatment (%)
Beta-blocker 20,851 (40.3)
ACE inhibitor/ARB 16,868 (32.6)
Statin 21,462 (41.5)
Platelet inhibitor 21,209 (41.0)
Loop diuretic 6663 (12.9)
Spironolactone 1733 (3.4)
Vitamin K antagonist 2505 (4.8)
Glucose lowering medication 5734 (11.1)
NSAID 3465 (6.7)
Antidepressive medication 4569 (8.8)
Comorbidity (%)
Myocardial infarction 31,078 (60.1)
Cardiac dysrhythmia 4759 (9.2)
Diabetes with complications 2117 (4.1)
Cerebrovascular disease 1373 (2.7)
Pulmonary edema 187 (0.4)
Shock 593 (1.2)
Cancer 424 (0.8)
Acute renal failure 331 (0.6)
Chronic renal failure 592 (1.1)
Chronic renal failure 1904 (3.7)
pulmonary disease
ACE: angiotensin-converting enzyme inhibitor; ARB: angiotensin 2 receptor blocker;procedures, with no significant differences between
patients with severe psoriasis and patients without
psoriasis (Tables 1 and 2). In the majority (88.3%) of
baseline previous myocardial infarctions the event date
was less than 30 days from the index PCI. At base-
line, patients with psoriasis received more non steroid
anti-inflammatory drugs (NSAIDs) and more antihyper-
tensive, cholesterol-lowering, glucose-lowering, and anti-
depressive medication, respectively, than patients without
psoriasis.
Patients who survived to enter the sensitivity analyses
with follow-up start at day 30 after the index PCI had a
similar gender distribution and the prevalence of psoria-
sis in this analysis was similar (2.7%). There were also no
differences in the proportion of (index) primary PCI pro-
cedures between the groups in this population. Patients
with severe psoriasis generally received significantly less
secondary prevention medication including beta-blockers,
statins, and platelet inhibitors. Furthermore, as in theMild psoriasis Severe psoriasis p–value
n=1074 n=315
767 (71.4) 193 (61.3) 0.003
307 (28.6) 122 (38.7)
65.0 (10.7) 63.5 (10.9) 0.06
434 (40.4) 132 (41.9) 0.60
381 (35.5) 121 (38.4) 0.003
506 (47.1) 136 (43.2) 0.003
490 (45.6) 133 (42.2) 0.02
139 (12.9) 48 (15.2) 0.33
38 (3.5) 11 (3.5) 0.74
48 (4.5) 11 (3.5) 0.23
123 (11.5) 52 (16.5) 0.01
101 (9.4) 36 (11.4) <0.001
125 (11.6) 42 (13.3) <0.001
596 (55.5) 182 (60.0) 0.008
115 (10.7) 28 (3.2) 0.33
38 (3.5) 22 (7.0) 0.20
33 (3.1) 10 (3.2) 0.32
5 (0.5) 2 (0.6) 0.33
6 (0.6) 8 (2.5) 0.62
9 (0.8) 3 (1.0) 0.62
2 (0.2) 3 (1.0) 0.46
8 (0.2) 4 (1.1) 0.51
50 (4.7) 15 (4.8) 0.06
NSAID: Non-steroid anti-inflammatory drug.
Table 2 Post PCI characteristics at 30, 180, and 360 days from index PCI
30 days after PCI No psoriasis Mild psoriasis Severe psoriasis p–value
n= 49,696 n=1027 n=309
Male (%) 35,632 (72.7) 737 (72.8) 192 (62.1) 0.007
Female (%) 14,064 (28.3) 290 (28.2) 117 (37.9)
Primary PCI (%) 14,451 (29.1) 268 (26.1) 90 (29.1) 0.17
Treatment (%)
Beta-blocker 38,916 (78.3) 772 (75.2) 230 (74.4) 0.005
ACE inhibitor/ARB 25,032 (50.4) 509 (49.6) 167 (54.1) 0.54
Statin 42,844 (86.2) 896 (86.3) 245 (79.3) 0.049
Platelet inhibitor 47,949 (96.5) 991 (96.5) 285 (92.2) 0.003
Dual anti-platelet inhibition 45,901 (92.4) 946 (92.1) 273 (88.4) 0.029
Loop diuretic 9812 (19.7) 201 (19.6) 71 (23.0) 0.34
Spironolactone 2852 (5.7) 53 (5.2) 23 (7.4) 0.67
Vitamin K antagonist 2904 (5.8) 58 (5.7) 18 (5.8) 0.85
Glucose-lowering medication 5586 (11.2) 112 (10.9) 52 (16.8) 0.039
NSAID 1349 (2.7) 40 (3.9) 34 (11.0) 0.002
180 days after PCI No psoriasis Mild psoriasis Severe psoriasis p–value
n= 46,126 n=955 n=279
Beta-blocker 36,431 (78.9) 727 (76.1) 212 (76.0) 0.05
ACE inhibitor/ARB 23,324 (50.6) 484 (50.7) 153 (54.8) 0.36
Statin 40,140 (87.0) 842 (88.2) 226 (81.0) 0.007
Platelet inhibitor 44,696 (96.9) 927 (97.1) 260 (93.2) 0.002
Dual anti-platelet inhibition 42,822 (92.8) 889 (93.1) 249 (89.3) 0.07
Loop diuretic 8968 (19.4) 188 (19.7) 62 (22.2) 0.50
360 days after PCI No psoriasis Mild psoriasis Severe psoriasis p–value
n= 42,188 n=860 n=257
Beta-blocker 33,507 (79.4) 665 (77.3) 195 (75.9) 0.124
ACE inhibitor/ARB 21,389 (50.7) 430 (50.0) 140 (54.5) 0.44
Statin 36,918 (87.5) 769 (89.4) 210 (81.7) 0.005
Platelet inhibitor 40,985 (97.2) 840 (97.7) 239 (93.0) <0.001
Dual anti-platelet inhibition 39,318 (93.2) 811 (94.3) 228 (88.7) 228 (88.7)
Loop diuretic 8055 (19.1) 161 (18.7) 52 (20.3) 0.86
PCI: percutaneous coronary intervention; ACE: angiotensin-converting enzyme inhibitor; ARB: angiotensin 2 receptor blocker; NSAID: Non-steroid anti inflammatory
drug.
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to receive NSAIDs, antidepressive medication, and
glucose-lowering drugs. An overview of post-PCI treat-
ment is presented in Table 2.
Post PCI prognosis
Psoriasis was associated with an increased risk of both
study endpoints (p-value for trend 0.004 and 0.007 for
all cause mortality and the composite endpoint, respect-
ively). In analyses stratified for psoriasis severity patients
with severe psoriasis, but not those with mild disease
had significantly increased prevalence of both study end-
points compared to patients without psoriasis. The inci-
dence rates (IRs) and 95% confidence intervals (CIs) forall-cause mortality were 30.5 (CI 29.7-31.3), 29.9 (CI
24.7-36.1), and 47.2 (CI 35.0-63.6) for patients without
psoriasis, with mild psoriasis, and with severe psoriasis,
respectively. The corresponding IRs for the composite
endpoint of death, myocardial infarction, and stroke
were 38.9 (CI 38.1.8-39.9), 37.3 (CI 31.4-44.4), and 55.4
(CI 41.8-73.5). In the primary analysis with start of
follow-up at the time of the index PCI and adjustment
for age and sex, the hazard ratios (HRs) for all cause
mortality were 1.10 (CI 0.91-1.33) and 1.83 (CI 1.36-
2.47) for mild and severe psoriasis, respectively (Table 3).
For the composite endpoint the corresponding age and
sex adjusted HRs were 1.07 (CI 0.90-1.27) for mild psor-
iasis and 1.65 (CI 1.24-2.19) for severe psoriasis. The
Table 3 Number of events, incidence rates, adjusted HRs, and 95% CI
Number of events Incidence rate 95% CI Hazard ratio 95% CI
All cause mortality
Follow-up start at index PCI
Mild psoriasis 107 29.9 24.7-36.1 1.10 0.91-1.33
Severe psoriasis 43 47.2 35.0-63.6 1.67 1.24-2.26
Follow-up start at day 30
Mild psoriasis 85 24.3 19.7-30.1 1.13 0.91-1.40
Severe psoriasis 38 42.8 31.1-58.8 1.78 1.30-2.46
Composite endpoint
Follow-up start at index PCI
Mild psoriasis 128 37.3 31.4-44.4 1.07 0.90-1.28
Severe psoriasis 48 55.4 41.8-73.5 1.54 1.16-2.05
Follow-up start at day 30
Mild psoriasis 90 26.9 21.9-33.1 1.10 0.90-1.36
Severe psoriasis 38 45.1 45.1 32.8-61.1 1.66 1.21-2.28
HR: hazard ratio; CI: confidence interval; PCI: percutaneous coronary intervention.
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index PCI and inclusion of post-PCI medication in the
Cox regression model gave similar results. The age- and
sex-adjusted estimates for all cause mortality were HR
1.11 (CI 0.89-1.37) and HR 2.06 (CI 1.50-2.84), for mild
and severe psoriasis, respectively. For the composite end-
point the corresponding age and sex adjusted HRs were
1.08 (CI 0.88-1.34) for mild psoriasis and 1.90 (CI 1.38-
2.62) for severe psoriasis (Table 3).
Repeat revascularization
There was a nonsignificant trend (p = 0.23) for increased
repeat revascularization rates in patients with psoriasis
compared to patients without psoriasis. IRs were 66.9
(CI 65.6-68.3), 71.3 (CI 62.2-81.6), and 75.0 (CI 57.7-
97.5), for patients without psoriasis, with mild psoriasis,
and with severe psoriasis, respectively. The corresponding
adjusted HRs were 1.05 (CI 0.89-1.22) and 1.14 (CI 0.85-
1.52) for mild and severe psoriasis, respectively.
Discussion
This nationwide study of the impact of psoriasis on prog-
nosis following PCI demonstrated an increased risk of all-
cause mortality and of a composite of death, myocardial
infarction, and stroke, respectively, in patients with severe
disease compared to subjects without psoriasis. The post-
PCI prognosis in patients with mild psoriasis was compar-
able to that of patients without psoriasis. Furthermore,
patients with severe psoriasis were less likely to receive
beta-blockers, statins and platelet inhibitors after PCI.
Psoriasis and atherosclerosis are chronic inflammatory
diseases characterized by T-helper (Th) 1-/Th17-driven
inflammation and there is an apparent overlap of inflam-
matory mechanisms in these diseases [1,2]. Psoriasis haspreviously been associated with increased prevalence of
conventional cardiovascular risk factors as well as cardio-
vascular morbidity and mortality [4-9,13-16]. Inflamma-
tion has also been suggested to contribute to post-PCI
complications including restenosis, in-stent thrombosis
and mortality [17]. Very limited data are available, how-
ever, on the impact of inflammatory diseases on the prog-
nosis after PCI. A small study of patients with systemic
lupus erythematosus demonstrated a worse 1-year out-
come compared to controls while a very small study of
patients with rheumatoid arthritis found no differences
between groups [18,19]. On the other hand, the current
demonstration of impaired prognosis after PCI in patients
with severe psoriasis is likely to contribute to the adverse
contemporary post-myocardial infarction prognosis found
in patients with this disease, as well as in post-myocardial
infarction subjects with systemic lupus erythematosus
and rheumatoid arthritis [12,20-22].
In the present study, patients with psoriasis were
more likely to receive statins, angiotensin converting
enzyme (ACE) inhibitors/angiotensin 2 receptor antago-
nists, glucose-lowering drugs, and platelet inhibitors at
baseline before index PCI than patients without psoriasis,
supportive of previous reports of an increased prevalence
of hypertension, hypercholesterolemia and diabetes mel-
litus in patients with psoriasis [7,23-29]. Also, in patients
with psoriasis there was a higher proportion of NSAID
users and medically managed depression compared to
patients without psoriasis, both of which have been asso-
ciated with impaired prognosis in patients with coronary
artery disease [30-32]. After adjustments for these and
other measured confounders, however, we found that
severe psoriasis was a risk factor for adverse prognosis
following first-time PCI, this suggests that the poor
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ences in comorbidity. It is noteworthy that the propor-
tion of high risk patients, i.e., where the index PCI was
performed in the setting of MI, and that the rates of
(index) primary PCI procedures (indicative of ST eleva-
tion myocardial infarction) were similar between
patients with severe psoriasis and patients without psor-
iasis. Also, the proportion of patients treated with loop
diuretics was similar irrespective of psoriasis status. This
indicates a comparable distribution of severe congestive
heart failure and is an important observation since we
were unable to control for baseline and post-PCI left ven-
tricular ejection fraction. Repeat revascularization rates
after index PCI were also not statistically different be-
tween patients with and without psoriasis, but our study
suggested differences in post-PCI pharmacological treat-
ment, with patients with severe psoriasis receiving less
beta-blockers, statins, and platelet inhibitors (Table 2).
Although the reasons underlying the latter observation
were not examined, significant chronic comorbidity has
been associated with suboptimal post-myocardial infarc-
tion care and this particular finding may be an example of
the treatment-risk paradox in coronary artery disease, i.e.,
that patients at increased risk receive relatively less
evidence-based treatment [33]. In contrast, our previous
report on prognosis after myocardial infarction in
patients with psoriasis in the time period 2002–06
demonstrated no significant differences in post-
myocardial infarction medical treatment, but that study
included fewer patients and did not specifically evaluate
the impact of psoriasis severity. Importantly, the analyses
that controlled for these differences in post-PCI treat-
ment gave results comparable to the primary analysis in-
dicating that the impaired post-PCI prognosis in patients
with severe psoriasis was not mainly driven by these dif-
ferences. Taken together, the current finding of impaired
post-PCI prognosis in patients with severe psoriasis
therefore supports the notion that psoriasis-driven
chronic inflammation per se may be an important deter-
minant of the observed differences in post-PCI prognosis.
This interpretation of the data reflects the sum of other
current evidence on mechanisms underlying increased
risk of cardiovascular disease in patients with chronic in-
flammatory diseases [3,6-11,14,15]. Accepted risk scores
for prognosis after myocardial infarction may therefore
underestimate the risk in these patients, as is the case for
primary prevention, where traditional risk factor algo-
rithms for coronary artery disease, e.g., the Framingham
risk score, are unlikely to capture the full extent of
increased risk [13,34-36].
Important strengths of the present study included the
large number of participants, the ability to evaluate a
psoriasis activity dose–response effect, the nationwide
coverage in prospectively recorded registries, thecontemporary clinical setting, and the completeness of
follow-up. Furthermore, the use of nationwide registries
of hospitalization data and dispensed prescriptions from
all pharmacies in Denmark where healthcare is readily
accessible and essentially free of charge minimized selec-
tion bias related to factors such as gender, age, socioeco-
nomic status, healthcare insurance provision and job
situation. Some limitations of our study should also be
acknowledged. The results relied on the accuracy of the
underlying registration in the registers, e.g., in terms of the
study population and outcome measures. The register
coding of revascularization procedures has not been vali-
dated but it is highly unlikely that the coding of these ex-
pensive and very specific treatments are erroneous. Also,
misclassification in relation to psoriasis status is likely to
be non-differential. The examined psoriasis cohort was
based on prescriptions filled for topical vitamin D deriva-
tives and our results may not apply to patients treated
with other first-line antipsoriatic drugs, e.g., topical corti-
costeroids. However, there is no obvious reason to suspect
important differences in baseline characteristics between
patients treated with topical vitamin D or other first-line
antipsoriatic drugs. Importantly, we have previously
demonstrated that the criteria for the psoriasis diagnosis
and severity classification in our registries were valid [14].
Because the Danish population is predominantly of
Caucasian descent, the results should only be extrapo-
lated to other ethnicities with caution. Finally, we were
unable to account for some important cardiovascular risk
factors, e.g., family history, obesity, and smoking, and
other prognostic variables including coronary pathologic
findings, PCI procedural variables, and left ventricular
ejection fraction, and we cannot exclude the possibility
unmeasured and/or residual confounding contributed to
our findings. However, information on strong predictors
of post-PCI adverse events, i.e., hypertension, diabetes
mellitus, renal failure, and adherence to dual anti-platelet
therapy were included [37].
Conclusion
This first study of the post-PCI prognosis in patients
with psoriasis demonstrated an increased risk of mortal-
ity and adverse cardiovascular events in patients with se-
vere psoriasis compared to patients without psoriasis.
These findings emphasize the increased burden of car-
diovascular disease in patients with psoriasis and they
call for further studies in this area of research.
Methods
The study was a retrospective longitudinal cohort study
using Danish nationwide prospectively recorded regis-
tries. The study complied with the Strengthening the
Reporting of Observational Studies in Epidemiology
(STROBE) recommendations [38].
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This study was approved by The Danish Data Protection
Agency (ref. 2008-41-2685). Approval from an ethics
committee is not required for administrative register
studies in Denmark.
Study population and data sources
The present study population comprised all subjects
from the entire Danish population, who underwent a
first-time PCI (Nordic classification of surgical proce-
dures code KFNG) in the period 2002–2009. Primary
PCI in patients with ST elevation myocardial infarction
was identified by the procedural codes KFNG02A and
KFNG05A. Patients were followed until December 31
2009, emigration, or to the occurrence of an endpoint.
Patients with PCI prior to the start of the study period
were excluded. All Danish citizens have a unique lifelong
personal civil registration number that enables linkage of
information on an individual level across nationwide pro-
spectively recorded registries. All medications dispensed
from pharmacies were obtained from the Danish Registry
of Medicinal Product Statistics, in which all dispensed
prescriptions since 1995 are registered. Morbidity was
obtained from the Danish National Patient Register in
which hospital admissions, procedures, and diagnoses
have been recorded since 1978 with the International
Classification of Diseases (ICD) codes. Deaths were iden-
tified from the Central Population Register, wherein all
deaths are recorded within 2 weeks. Socioeconomic
status was defined as average yearly income in a period
of up to 5 years prior to inclusion and divided into
quintiles.
Psoriasis identification
Patients with mild psoriasis were identified according to
prescriptions claimed prior to study inclusion (index
PCI) for topical treatment used exclusively for psoriasis,
i.e., topical vitamin-D derivatives (ATC D05AX). Subjects
with severe psoriasis were identified by hospitalizations
for psoriasis and psoriatic arthritis (ICD-10 L40 and
M07.0-M07.3), respectively, from 1994 to index PCI, as
validated previously [9,14].
Medical treatment and comorbidity
Medical treatment for cardiovascular diseases and cardio-
vascular risk factors, including hypertension, dyslipidemia,
and diabetes mellitus were identified by prescriptions for
platelet inhibitors (ATC code: B01AC), beta-blockers
(C07), ACE inhibitors/angiotensin 2 receptor antagonists
(C09), loop diuretics (C03C), spironolactone (C03D), sta-
tins (C10A), and glucose-lowering drugs (A10) claimedup to 6 months prior to index PCI. Use of NSAID
(M01A) and anti-depressive medication (N06A) was also
ascertained. Initiation and adherence to cardiovascular
secondary prophylaxis was evaluated at 30, 180, and
360 days from the index PCI. Comorbidity was defined
by hospitalizations up to 12 months prior to the index
PCI according to the Ontario myocardial infarction
mortality prediction rule as adapted to ICD 10 [39].
Outcomes
The primary study endpoint was all-cause mortality and
a secondary composite endpoint was death, recurrent
myocardial infarction (ICD-10 I21-I22) and stroke (ICD-
10 I60, I61, I63, and I64). Repeat revascularization rates
after index PCI were also determined, including PCI and
coronary artery bypass grafting. The myocardial infarc-
tion and stroke diagnoses in the Danish registries have
previously been found valid [40,41].
Statistical analysis
Baseline characteristics were summarized and presented
as means with standard deviations (SD) and percentages.
Differences in baseline characteristics were assessed by
analyses of variance (ANOVA) and by chi-square test for
categorical covariates. IRs of study endpoints were
reported as events per 1000 patient-years. The HRs and
corresponding CIs were estimated by Cox regression
models controlling for confounding factors including
calendar year, patient age, gender, baseline use of medi-
cation and comorbidity, and socioeconomic data. A sen-
sitivity analysis with start of follow-up 30 days from
the index PCI and inclusion of post-PCI medication in
the regression model was also done in order to assess the
impact of differences in post-PCI treatment between the
groups. Age- and sex-adjusted models, and a fully adjusted
model with inclusion of age, sex, medication, comorbidity,
and socioeconomic status, were fitted. Model assump-
tions, including absence of interaction between model
covariates and the proportional hazard assumption were
tested and found to be valid. A two-sided p <0.05 was
considered statistical significant. All statistical analyses
were performed with the SAS statistical software version
9.2 (Sas Institute inc., Cary, NC, USA) and Stata software
version 11 (Statacorp, College st., TX, USA).
Abbreviations
PCI: Percutaneous coronary intervention; IR: Incidence rate; HR: Hazard ratio;
CI: 95% Confidence interval; NSAID: Non steroid anti-inflammatory drugs;
ACE: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin 2 receptor
blocker.
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